Loading...
XSHE
300109
Market cap1.10bUSD
Oct 09, Last price  
12.92CNY
1D
1.33%
1Q
-8.11%
Jan 2017
-65.54%
IPO
-14.87%
Name

Boai NKY Medical Holdings Ltd

Chart & performance

D1W1MN
XSHE:300109 chart
P/E
39.21
P/S
6.33
EPS
0.33
Div yield, %
1.63%
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
-0.70%
Revenues
1.18b
-26.66%
108,683,239130,085,199163,311,320190,734,549212,847,086209,389,953253,343,475290,639,760400,618,888488,581,463698,283,177924,426,291978,529,1091,220,275,2461,220,275,2461,485,693,9051,485,693,9051,583,417,8421,606,320,0271,178,091,965
Net income
190m
-45.64%
10,348,85318,208,38023,026,68024,921,07520,073,30120,165,06930,117,86656,985,66280,039,83592,823,19589,546,173122,796,22944,574,979293,119,661207,047,720291,463,635291,463,644493,027,341349,680,190190,085,387
CFO
338m
+32.06%
9,560,192028,571,73310,052,6243,941,49820,648,17623,172,95546,599,08264,116,278114,144,48847,279,35948,810,50979,638,058266,871,09043,440,305251,768,613488,252,026256,030,360338,106,365
Dividend
Jun 23, 20260.24 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Boai NKY Medical Holdings Ltd. is an international enterprise specializing in the development, production, and global distribution of polyvinylpyrrolidone (PVP) series products. Its extensive product portfolio features pharmaceutical excipients such as Povidone, Crospovidone, and Copovidone, marketed under the KoVidone and PolyKoVidone brand lines. The company also manufactures OraRez PVM/MA copolymers and their derivatives, which are specialized functional polymers vital for bioadhesive and mucoadhesive applications. Additionally, it supplies KoVidone-1, a broad-spectrum agent with biocidal, antifungal, and antiviral efficacy. Further offerings encompass a wide array of chemical solutions, including pharmaceutical solvents, intermediates, various polymers, and vinyl and vinyl ether compounds. Specific branded products like PolyViscol, KoVidone I, WhiVidone, and PVPP are also part of their catalog. These diverse chemical components find integral application across numerous industries, including pharmaceuticals, industrial processes, oral care products, cosmetics, and the food and beverage sector. Founded in Heping, China, in 1987, the company was initially known as Boai NKY Pharmaceuticals Ltd. It transitioned to its current designation, Boai NKY Medical Holdings Ltd., in March 2016.

Key people

Wei Zhao
Vice Chairman of the Board · since 2019
Aimin Liu
Chief Financial Officer · since 2012
Xianghua Ding
Deputy General Manager · since 2011
Shegang Li
Deputy General Manager · since 2023
Dan Liu
Deputy General Manager · since 2019
Haizhan Mao
Deputy General Manager · since 2023
Dalong Ren
Deputy General Manager · since 2019
Shigang Wang
Deputy General Manager · since 2023
Xinmeng Wang
Deputy General Manager · since 2019
Jiangtao Yu
Senior Deputy General Manager, Director · since 2023
Dedong Zhang
Deputy General Manager · since 2011
Xiaowen Zou
Deputy General Manager · since 2019
Xiaoliang Xing
Deputy General Manager, Secretary of the Board · since 2019
Yunxia Qu
Senior Deputy General Manager, Director · since 2023
Donghu Wang
Director · since 2021
Hongbo Yang
Vice Chairman of the Board · since 2019
Junzheng Zhang
Chairman of the Board, General Manager · since 2023
Yongjun Fang
Independent Director · since 2022
Zhigang Xue
Independent Director · since 2025
Rui Zhao
Independent Director · since 2022
IPO date
Aug 25, 2010
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
河南省焦作市博爱县文化路(东段)1888号
焦作市, HA 450000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT